Life Science Investing Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Life Science Investing Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease
Life Science Investing Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Life Science Investing Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia
LaFleur Minerals Provides Update on PEA for the Restart of Beacon Gold Mill Sourcing Material from Its Swanson Gold Deposit, Val d'Or, Québec
